Tenaya Therapeutics (TNYA)
(Delayed Data from NSDQ)
$4.14 USD
-0.40 (-8.81%)
Updated May 28, 2024 04:00 PM ET
After-Market: $4.16 +0.02 (0.48%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Tenaya Therapeutics, Inc. (TNYA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$19.29 | $40.00 | $7.00 | 324.89% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Tenaya Therapeutics, Inc. comes to $19.29. The forecasts range from a low of $7.00 to a high of $40.00. The average price target represents an increase of 324.89% from the last closing price of $4.54.
Analyst Price Targets (7 )
Broker Rating
Tenaya Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, eight are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 8 | 8 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/15/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
5/15/2024 | SVB Securities | Mani Foroohar | Strong Buy | Strong Buy |
5/15/2024 | LifeSci Capital | Cory Jubinville | Strong Buy | Strong Buy |
3/20/2024 | Canaccord Genuity | Whitney Ijem | Strong Buy | Strong Buy |
3/1/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
3/1/2024 | Chardan Capital Markets | Yevgeniya Livshits | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 8 |
Average Target Price | $19.29 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 89 of 252 |
Current Quarter EPS Est: | -0.40 |